Preveceutical Stock Price, News & Analysis

PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board effective December 1, 2024. Dr. Gallagher brings over 25 years of experience in biotech and pharmaceutical investments, having served as Managing Partner at Trekk Venture Partners and Partner at Abingworth. His notable achievements include overseeing Sirtris Pharmaceuticals' $720 million acquisition by GlaxoSmithKline and contributing to Translate Bio's $3.2 billion acquisition by Sanofi.

Dr. Gallagher holds a Ph.D. in Organic Chemistry from the University of Michigan and has served as Chairman of eFFECTOR Therapeutics. His expertise spans venture capital, strategic investments, and corporate development within the biotech sector.

PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Stephen Glover as an independent director effective November 30, 2024. The company's CEO, Stephen Van Deventer, highlighted Glover's expertise in biopharma, corporate strategy, commercialization, and financial management, noting his track record in building and transforming organizations aligns with BioGene's mission to advance groundbreaking therapies.

PreveCeutical Medical's subsidiary BioGene Therapeutics has appointed Dr. Deepak Sampath as an independent director effective November 21, 2024. Dr. Sampath brings over 25 years of experience in molecular biology, pharmacology, and drug development. Currently serving as Senior Vice President and Head of Research at Ultragenyx, he has contributed significantly to oncological treatments, including the FDA approval of venetoclax for CLL/SLL. His expertise spans protein biologics, nucleic acids, and gene therapies, with 108 published articles and involvement in 32 patents/applications. At Ultragenyx, he leads research in genetic conditions across neurological, metabolic, bone, and muscular diseases.

PreveCeutical Medical announced that its subsidiary BioGene Therapeutics has appointed Professor Mirela Delibegovic, FRSE to its Scientific Advisory Board effective November 19, 2024. The company, which focuses on developing preventive and curative therapies using organic and nature-identical products, expects to benefit from Delibegovic's expertise in obesity and diabetes physiology and signaling research to advance their therapeutic programs in metabolic health.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) has announced two key appointments at its subsidiary BioGene Therapeutics Inc. Dr. Linnea Olofsson joins as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer, effective November 16, 2024. Dr. Parekh brings over two decades of experience in pharmaceutical chemistry and drug/gene delivery systems from The University of Queensland's School of Pharmacy. Dr. Olofsson contributes expertise in biophysics, oncology, molecular biology, and CRISPR/Cas9 gene editing. These appointments aim to advance BioGene's scientific initiatives and therapeutic applications development.

PreveCeutical Medical has completed the intellectual property asset sale transaction with its subsidiary BioGene Therapeutics. The transaction, valued at USD$1,353,227, involves PreveCeutical and PreveCeutical Australia selling certain intellectual property assets to BioGene. The payment structure includes USD$500,000 in cash to be paid within 24 months and 16,000,000 common shares of BioGene at USD$0.0533 per share. PreveCeutical plans to distribute a portion of these shares to its shareholders at a future date.

PreveCeutical Medical has announced the appointment of Dr. Mariya Georgieva as President of its wholly-owned subsidiary BioGene Therapeutics, effective November 11, 2024. Dr. Georgieva joins from AstraZeneca where she served as Director of Diagnostic Alliances in Precision Medicine R&D since 2019. Previously, she headed applications and business development at Oxford-based ONI. She holds a PhD in Biomedical Science from the University of Montpellier, specializing in single-molecule fluorescence tools for studying epigenetic alterations.

PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) has signed a definitive agreement to sell intellectual property assets to BioGene Therapeutics, its wholly owned subsidiary, for USD$1,353,227. The deal includes IP from UniQuest's research program and bio-responsive gene carrier systems for siRNA delivery in diabetes and obesity treatment. The purchase price consists of USD$500,000 in cash (payable within 24 months) and 16,000,000 common shares of BioGene at USD$0.0533 per share. PreveCeutical plans to distribute approximately 75% of the consideration shares to its shareholders on a pro-rata basis, with details and record date to be announced.

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) has engaged Phoenix Corporate Finance Inc. to provide strategic and corporate advisory services for potential future transactions. Phoenix, based in Toronto, will advise on potential strategic transactions, including asset acquisitions or dispositions. As compensation, PreveCeutical will pay Phoenix $30,000 plus applicable taxes.

Stephen Van Deventer, Chairman and CEO of PreveCeutical, stated that as the company transitions from R&D to the clinical phase, they believe strategic partnerships and a new approach to their four research programs will be necessary. The company plans to allocate additional resources and talent to each program, specific to their respective medical fields.